

As of 8/13/2021, the FDA has approved the use of the Pfizer and Moderna COVID-19 vaccines to be used as a 3rd booster injection for all people that initially completed the Pfizer or Moderna COVID-19 vaccination series and are currently utilizing immunosuppressive medications. These medications include:

- Methotrexate (Rasuvo, Otrexup, Trexall)
- Azulfidine (Sulfasalazine)
- Arava (Leflunomide)
- Prednisone  $\geq$  20mg daily
- TNF inhibitors (Enbrel, Humira, Simponi, Remicade, Cimzia)
- JAK inhibitors (Xeljanz, Rinvoq, Olumiant)
- Orencia
- IL-6 inhibitors (Actemra, Kevzara)
- Rituxan
- IL-1 inhibitors (Kineret, Ilaris)
- IL-17 inhibitors (Cosentyx, Taltz)
- IL23 inhibitors (Tremfya)
- IL12-23 inhibitors (Stelara)
- Benlysta
- Imuran (Azathioprine)
- Cellcept (Mycophenolate)
- Cyclosporin
- Tacrolimus

It is recommended to receive the same brand of vaccine initially completed when possible.

Booster injections may be administered beginning 28 days after completing the second dose of either Pfizer or Moderna.

Booster injections are currently not recommended for people who initially received the Johnson & Johnson Vaccine. The Johnson & Johnson vaccine has not been approved as an option for boosters at this time.

The American College of Rheumatology has recommendations on how to time your vaccine with your medication to insure maximized vaccine response. Please see below for the current recommendations.

**No modifications to either immunomodulatory therapy or vaccination timing:**

- Azulfidine (Sulfasalazine)
- Arava (Leflunomide)
- TNF inhibitors (Enbrel, Humira, Simponi, Remicade, Cimzia)
- IL-6 inhibitors (Actemra, Kevzara)
- IL-1 inhibitors (Kineret, Ilaris)
- IL-17 inhibitors (Cosentyx, Taltz)
- IL23 inhibitors (Tremfya)
- IL12-23 inhibitors (Stelara)
- Benlysta
- Imuran (Azathioprine)
- Cellcept (Mycophenolate)
- Cyclosporin
- Tacrolimus

**HOLD therapy or time treatment around vaccine booster:**

- Methotrexate: Hold Methotrexate 1 week after vaccine booster for those patients with well controlled disease
- JAK Inhibitors (Xeljanz, Olumiant, Rinvoq): Hold JAKi for 1 week after vaccine booster
- Subcutaneous Orencia (Injections): Hold Orencia injections both one week prior to and one week after the vaccine booster
- IV Orencia (Infusions): Time vaccine administration so that the vaccine booster will occur four weeks after Orencia infusion (i.e., the entire dosing interval), and postpone the subsequent Orencia infusion by one week (i.e., a 5-week gap in total)
- Rituxan: Schedule vaccination so that the vaccine booster is initiated approximately 4 weeks prior to next scheduled Rituxan infusion cycle; after vaccination, delay Rituxan infusion 2-4 weeks after the vaccine booster, if disease activity allows
- Cyclophosphamide: Time Cyclophosphamide administration so that it will occur approximately 1 week after vaccine booster, when feasible